Self-Monitoring of Blood Glucose Requirements with the Use of Intermittently Scanned Continuous Glucose Monitoring.
Adult
Blood Glucose
/ analysis
Blood Glucose Self-Monitoring
/ instrumentation
Calibration
Diabetes Mellitus, Type 1
/ blood
Female
Humans
Hypoglycemia
/ chemically induced
Hypoglycemic Agents
/ therapeutic use
Insulin
/ therapeutic use
Male
Middle Aged
Randomized Controlled Trials as Topic
Time Factors
Flash glucose monitoring
Hypoglycemia
Intermittently scanned continuous glucose monitoring
Type 1 diabetes
Journal
Diabetes technology & therapeutics
ISSN: 1557-8593
Titre abrégé: Diabetes Technol Ther
Pays: United States
ID NLM: 100889084
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
14
12
2019
medline:
23
1
2021
entrez:
14
12
2019
Statut:
ppublish
Résumé
Current intermittently scanned continuous glucose monitoring (isCGM) devices do not allow calibration and require confirmatory self-monitored blood glucose (SMBG) under specific defined conditions. The overall time spent in an SMBG-indicated state while using isCGM has not been reported in the existing literature. We present the time spent in an SMBG-indicated state and the daily number of transitions to an SMBG-indicated state during isCGM use in a high-risk cohort of adults with type 1 diabetes. This is a post hoc analysis of participants randomized to isCGM as part of a clinical study. The percentage of values meeting one or more of the criteria for SMBG testing (hours per day) and the number of transitions to an SMBG-indicated state per day were calculated according to the manufacturer's label in the United Kingdom. Complete data sets for 20 participants on isCGM for 8 weeks were included in the analysis. Participants spent a mean (SD) of 5.61 (1.81) h/day in an SMBG-indicated state and there were 5.43 (1.42) transitions to an SMBG-indicated state per day while using isCGM. These findings have important implications for cost-effectiveness and for decision-making around insulin dose calculations and driving. Our findings emphasize the need for continued SMBG testing among people at high risk of hypoglycemia who use isCGM. Cost-effectiveness analyses for isCGM may require revision.
Identifiants
pubmed: 31833786
doi: 10.1089/dia.2019.0369
pmc: PMC7047107
doi:
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
235-238Références
Lancet. 2016 Nov 5;388(10057):2254-2263
pubmed: 27634581
Diabet Med. 2018 Apr;35(4):483-490
pubmed: 29230878
Eur Endocrinol. 2018 Sep;14(2):73-79
pubmed: 30349598
Diabetes Technol Ther. 2019 Nov 14;:
pubmed: 31724878
BMJ Open Diabetes Res Care. 2017 Apr 6;5(1):e000342
pubmed: 28611921
Diabetologia. 2019 Aug;62(8):1349-1356
pubmed: 31177314
Diabetes Res Clin Pract. 2018 Apr;138:193-200
pubmed: 29410149